Brief: Synlogic Receives Positive Opinion On Orphan Designation From European Medicines Agency For SYNB1618 For Treatment Of Phenylketonuria
Synlogic Inc reports results for the quarter ended in March - Earnings Summary
Brief: Synlogic Posts Q1 Loss Per Share Of 22 Cents
Synlogic Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Synlogic To Present At 2022 Genetic Metabolic Dieticians International (Gmdi) Conference
U.S. RESEARCH ROUNDUP-Digitalbridge Group, Joann, Park Ohio Holdings
Synlogic Inc reports results for the quarter ended in December - Earnings Summary
Brief: Synlogic Reports Fourth Quarter And Full Year 2021 Financial Results
Synlogic Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Synlogic Announces Appointment Of Michael Jensen As Chief Financial Officer
Brief: Synlogic Says It Is On Track To Initiate Phase 3 For PKU Treatment In H2
U.S. STOCKS ON THE MOVE-HP Inc, Gap Inc, Nordstrom, Qualcomm
U.S. STOCKS ON THE MOVE-Zoom, Gap Inc, Chevron
U.S. STOCKS ON THE MOVE-Zoom, Tesla, Chevron
Synlogic jumps after Oppenheimer upgrades to 'outperform'
Brief: Synlogic Presents Data Demonstrating Reductions In Plasma Phenylalanine Levels In Patients With Phenylketonuria Treated With Synb1618
Synlogic Inc reports results for the quarter ended in September - Earnings Summary
Brief: Synlogic Reports Third Quarter Financial Results
Brief: Synlogic And Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine For The Treatment Of Homocystinuria